Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.51 |
| ▸ | BID | P55957 | 3/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.47 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.47 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.47 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1002751 | 0.98 | LMNA (0.58) | CYP3A4LMNAMEN1NR1I2CHRM2 | |
| SCHEMBL31079007 | 0.98 | LMNA (0.58) | CYP3A4LMNAMEN1NR1I2CHRM2 | |
| SCHEMBL1003626 | 0.98 | LMNA (0.58) | CYP3A4LMNAMEN1NR1I2CHRM2 | |
| SCHEMBL1004461 | 0.98 | LMNA (0.58) | CYP3A4LMNAMEN1NR1I2CHRM2 | |
| SCHEMBL421013 | 0.98 | LMNA (0.58) | CYP3A4LMNAMEN1NR1I2CHRM2 | |
| SCHEMBL1004554 | 0.98 | LMNA (0.58) | CYP3A4LMNAMEN1NR1I2CHRM2 | |
| SCHEMBL1002777 | 0.98 | LMNA (0.58) | CYP3A4LMNAMEN1NR1I2CHRM2 | |
| SCHEMBL5566506 | 0.98 | LMNA (0.58) | CYP3A4LMNAMEN1NR1I2CHRM2 | |
| SCHEMBL1003944 | 0.98 | LMNA (0.58) | CYP3A4LMNAMEN1NR1I2CHRM2 | |
| SCHEMBL28193718 | 0.98 | LMNA (0.58) | CYP3A4LMNAMEN1NR1I2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4065549-B1 | CANNABINOID DERIVATIVES | CANOPY GROWTH CORP (CA) | 2026-03-11 | — | — | EP | claimed |
| EP-4065549-A1 | CANNABINOID DERIVATIVES | Canopy Growth Corporation (CA) | 2022-10-05 | — | — | EP | claimed |
| WO-2021102568-A1 | CANNABINOID DERIVATIVES | CANOPY GROWTH CORPORATION (CA) | 2021-06-03 | — | — | WO | claimed |
| EP-3781142-A1 | NOVEL [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | Merck Sharp&Dohme Corp. (US) | 2021-02-24 | — | — | EP | claimed |
| CN-112107684-A | Methods and compositions for treating ARID2 or HSPA1A mediated diseases | 中国科学院分子细胞科学卓越创新中心 | 2020-12-22 | — | — | CN | claimed |
| WO-2019204180-A1 | NOVEL [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-10-24 | — | — | WO | claimed |
| CN-108864038-A | 3- amide groups-N- aryl benzamides class compound and preparation and application | 浙江大学 | 2018-11-23 | — | — | CN | claimed |
| CN-102762557-B | Triazolopyridine | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-10-07 | — | — | CN | claimed |
| CN-102762557-A | Triazolopyridines | BAYER SCHERING PHARMA AG | 2012-10-31 | — | — | CN | claimed |
| EP-1888595-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-02-20 | — | — | EP | claimed |
| WO-2006110917-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-10-19 | — | — | WO | claimed |
| US-12415822-B2 | Small molecule inhibitors selective for polo-like kinase protein | UNIVERSITY OF SOUTH CAROLINA (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250188201-A1 | CATALYST FOR PHOTOCATALYTIC POLYMERIZATION REACTION, AND APPLICATION THEREOF | BEIJING INSTITUTE OF FASHION TECHNOLOGY (CN) | 2025-06-12 | — | — | US | disclosed |
| CN-116217348-B | Preparation method of 1, 2-di-n-propoxybenzene | 万华化学集团股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117551039-A | Aryl formamide compound, preparation method thereof and application of aryl formamide compound in resisting enterovirus EV71 | 武汉大学 | 2024-02-13 | — | — | CN | disclosed |
| WO-1993023357-A1 | STILBENE DERIVATIVES AS ANTICANCER AGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| CN-1071930-A | Inhibitor as the human immunodeficiency virus protease who treats acquired immune deficiency syndrome (AIDS) | LILLY CO ELI (US) | 1993-05-12 | — | — | CN | disclosed |
| CN-1057194-A | Preparation and use of porphyrins | FMC CORP (US) | 1991-12-25 | — | — | CN | disclosed |
| EP-0323887-A2 | Heat-sensitive diazo recording materials | FUJI PHOTO FILM CO., LTD. (JP) | 1989-07-12 | — | — | EP | disclosed |
| US-4355178-A | BY ACYLATION OF THE CORRESPONDING UREA | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA R.T. (HU) | 1982-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12415822-B2 | Small molecule inhibitors selective for polo-like kinase protein | PLK2, PLK4, PLK3 | CYP3A4 4617/4885LMNA 1782/4885MEN1 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.